|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||51.34 - 51.75|
|52 Week Range||40.77 - 54.28|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.58%|
As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.
The following is original research by ARK's Genomic Revolution Analyst, Manisha Samy . Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in ...
Prime Minister May Looks to Bolster the Sector Earlier this year, Prime Minister Theresa May earmarked life sciences as one of five areas critical to the UK’s economic growth and commissioned a proposal on how to bolster the sector, especially as the ...
Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.
Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.
In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we'll look at its ...